QC
AXSM icon

Quadrature Capital’s Axsome Therapeutics AXSM Stock Holding History

Quadrature Capital’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16,459
Closed -$1.72M – 1045
2025
Q2 		$1.72M Buy
16,459
+2,306
+16% +$244K 0.03% 320
2025
Q1 		$1.65M Buy
+14,153
New +$1.61M 0.04% 327

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Quadrature Capital's AXSM Position: Q3 2025 in Review

Quadrature Capital sold out of Axsome Therapeutics (AXSM) in Q3 2025, closing a stake of 16,459 shares — an estimated $1.72M sold.

Quadrature Capital first reported a position in AXSM in Q1 2025 and held it in 2 quarters. The position peaked at $1.72M in Q2 2025. 355 funds tracked by Wall St. Rank hold AXSM as of Q3 2025.

  • Quadrature Capital reported no remaining Axsome Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Quadrature Capital sold 16,459 Axsome Therapeutics shares in Q3 2025, an estimated $1.72M.
  • Quadrature Capital first reported a position in Axsome Therapeutics in Q1 2025 and held it in 2 quarters.
  • Quadrature Capital's Axsome Therapeutics position peaked at $1.72M in Q2 2025.
  • 355 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2025.

Based on Quadrature Capital's 13F filing for Q3 2025, filed 13 Nov 2025.